Viewing Study NCT03284957


Ignite Creation Date: 2025-12-24 @ 6:56 PM
Ignite Modification Date: 2026-01-05 @ 5:24 PM
Study NCT ID: NCT03284957
Status: TERMINATED
Last Update Posted: 2025-11-24
First Post: 2017-09-13
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer
Sponsor: Sanofi
Organization: